The global market for Pharmacokinetics Services was estimated at US$1.0 Billion in 2023 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of 6.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
By partnering with CROs, these companies can take advantage of specialized pharmacokinetics services that are equipped with state-of-the-art bioanalytical tools and staffed by experts in drug metabolism and pharmacokinetics (DMPK). Outsourcing also offers the flexibility to scale services up or down based on the needs of individual drug development programs, making it a cost-effective solution for both early-stage and late-stage drug candidates. Additionally, the global reach of many CROs allows pharmaceutical companies to conduct pharmacokinetics studies across multiple geographic regions, which is crucial for addressing regulatory requirements in different markets.
Another key driver of outsourcing is the increasing complexity of new drug candidates, particularly in areas such as biologics, gene therapies, and personalized medicines. These complex therapeutics require highly specialized pharmacokinetics services, which CROs are well-positioned to provide. The rise of personalized medicine, in particular, is driving demand for pharmacokinetics studies that focus on individual variability in drug metabolism, distribution, and excretion, further fueling the growth of the outsourcing market.
Additionally, the increasing prevalence of biologics and biosimilars in the pharmaceutical pipeline has driven demand for advanced pharmacokinetics services. These complex molecules have unique pharmacokinetics profiles, requiring specialized analysis that goes beyond traditional small-molecule drugs. As more biologics enter clinical development, the need for tailored pharmacokinetics studies will continue to grow, particularly for therapies targeting oncology, autoimmune diseases, and rare genetic disorders.
The expansion of global clinical trials has also contributed to the growth of the pharmacokinetics services market. As pharmaceutical companies seek to bring drugs to market in multiple regions, they must comply with diverse regulatory requirements, necessitating region-specific pharmacokinetics data. This has led to increased demand for CROs that can conduct multi-regional studies and provide comprehensive pharmacokinetics data across various patient populations.
Lastly, the regulatory landscape continues to evolve, with agencies such as the FDA and EMA placing greater emphasis on pharmacokinetics data in drug approval processes. This has driven pharmaceutical companies to invest more heavily in pharmacokinetics studies to ensure regulatory compliance and minimize the risk of late-stage clinical failures. The growing complexity of regulatory requirements, particularly for novel therapies, is expected to further propel the demand for high-quality pharmacokinetics services.
How Is Outsourcing of Pharmacokinetics Services Influencing the Market?
The outsourcing of pharmacokinetics services to specialized contract research organizations (CROs) has become a prevalent trend, as pharmaceutical and biotechnology companies look to streamline their drug development pipelines. Outsourcing allows companies to access the latest technologies, expertise, and infrastructure without the need for significant internal investments. This trend is particularly strong among small to mid-sized pharmaceutical companies, which may lack the resources to conduct in-house pharmacokinetics studies.By partnering with CROs, these companies can take advantage of specialized pharmacokinetics services that are equipped with state-of-the-art bioanalytical tools and staffed by experts in drug metabolism and pharmacokinetics (DMPK). Outsourcing also offers the flexibility to scale services up or down based on the needs of individual drug development programs, making it a cost-effective solution for both early-stage and late-stage drug candidates. Additionally, the global reach of many CROs allows pharmaceutical companies to conduct pharmacokinetics studies across multiple geographic regions, which is crucial for addressing regulatory requirements in different markets.
Another key driver of outsourcing is the increasing complexity of new drug candidates, particularly in areas such as biologics, gene therapies, and personalized medicines. These complex therapeutics require highly specialized pharmacokinetics services, which CROs are well-positioned to provide. The rise of personalized medicine, in particular, is driving demand for pharmacokinetics studies that focus on individual variability in drug metabolism, distribution, and excretion, further fueling the growth of the outsourcing market.
What Are the Key Drivers of Growth in the Pharmacokinetics Services Market?
Growth in the pharmacokinetics services market is driven by several factors, including technological innovations, increasing complexity in drug development, and the rising trend of outsourcing. One of the primary drivers is the growing demand for personalized medicine, where pharmacokinetics studies are essential for understanding how individual genetic differences affect drug metabolism. This trend has expanded the market for pharmacokinetics services, as pharmaceutical companies require more precise and individualized data to support personalized treatment regimens.Additionally, the increasing prevalence of biologics and biosimilars in the pharmaceutical pipeline has driven demand for advanced pharmacokinetics services. These complex molecules have unique pharmacokinetics profiles, requiring specialized analysis that goes beyond traditional small-molecule drugs. As more biologics enter clinical development, the need for tailored pharmacokinetics studies will continue to grow, particularly for therapies targeting oncology, autoimmune diseases, and rare genetic disorders.
The expansion of global clinical trials has also contributed to the growth of the pharmacokinetics services market. As pharmaceutical companies seek to bring drugs to market in multiple regions, they must comply with diverse regulatory requirements, necessitating region-specific pharmacokinetics data. This has led to increased demand for CROs that can conduct multi-regional studies and provide comprehensive pharmacokinetics data across various patient populations.
Lastly, the regulatory landscape continues to evolve, with agencies such as the FDA and EMA placing greater emphasis on pharmacokinetics data in drug approval processes. This has driven pharmaceutical companies to invest more heavily in pharmacokinetics studies to ensure regulatory compliance and minimize the risk of late-stage clinical failures. The growing complexity of regulatory requirements, particularly for novel therapies, is expected to further propel the demand for high-quality pharmacokinetics services.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Small Molecules segment, which is expected to reach US$1.2 Billion by 2030 with a CAGR of a 6.1%. The Large Molecules segment is also set to grow at 7.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $271.9 Million in 2023, and China, forecasted to grow at an impressive 6.1% CAGR to reach $249.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Pharmacokinetics Services Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Pharmacokinetics Services Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Pharmacokinetics Services Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Global Pharmacokinetics Services Market such as Biologics Consulting Group, Inc., Certara L.P., Charles River Laboratories International, Inc., Creative Bioarray, Eurofins Scientific, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 34 companies featured in this Global Pharmacokinetics Services market report include:
- Biologics Consulting Group, Inc.
- Certara L.P.
- Charles River Laboratories International, Inc.
- Creative Bioarray
- Eurofins Scientific, Inc.
- Evotec AG
- Frontage Labs
- GVK Biosciences Private Limited
- LGC Limited
- Pacific BioLabs
- Parexel International Corporation
- Pharmaceutical Product Development, LLC
- Product Development, LLC (Jaguar Holding Company I, LLC)
- SGS SA
- Shanghai Medicilon Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned
Some of the 34 companies featured in this Global Pharmacokinetics Services market report include:- Biologics Consulting Group, Inc.
- Certara L.P.
- Charles River Laboratories International, Inc.
- Creative Bioarray
- Eurofins Scientific, Inc.
- Evotec AG
- Frontage Labs
- GVK Biosciences Private Limited
- LGC Limited
- Pacific BioLabs
- Parexel International Corporation
- Pharmaceutical Product Development, LLC
- Product Development, LLC (Jaguar Holding Company I, LLC)
- SGS SA
- Shanghai Medicilon Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 89 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1 Billion |
| Forecasted Market Value ( USD | $ 1.6 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
